Literature DB >> 32192853

Domain specific cognitive impairment in Parkinson's patients with mild cognitive impairment.

Shefali Chaudhary1, S Senthil Kumaran2, G S Kaloiya3, Vinay Goyal4, Rajesh Sagar5, M Kalaivani6, N R Jaganathan1, Nalin Mehta7, Achal Srivastava4.   

Abstract

Mild cognitive impairment (MCI) affects nearly 20-50% patients with Parkinson's disease (PD). It may be the prodromal stage of dementia and impacts quality of life of the patient and caregiver. Characterizing PD cognition at the stage of MCI may help in understanding of cognitive pathophysiology. This study assessed and compared cognition in patients with PD and mild cognitive impairment (PD-MCI, n = 32, age = 61.09 ± 5.97 years), PD patients with normal cognition (PD-NC, n = 32, age = 58.81 ± 6.15 years) and healthy controls (HC, n = 38, age = 57.39 ± 7.14 years). Montreal Cognitive Assessment Test (MoCA) was used for categorization of subjects. Cognitive assessment of five domains: executive function, attention, visuospatial function, memory and language (using two tests in each domain) were performed. The effect of PD clinical scores on cognition and cognitive domain specificity in diagnosing PD-MCI were assessed by correlation and receiver operating curve (ROC) analyses, respectively. All the analyses followed removal of potential confounds (age, education and clinical scores). Attention, memory, executive and visuospatial functions were impaired in PD-MCI on comparison with HC and PD-NC groups. Performance in digit span forward and trail making tests for attention and memory (immediate recall) were comparable in both the PD groups. Both the PD groups revealed impairment in attention, memory and language with respect to HC, suggesting the fronto-striatal and posterior cortical syndrome in PD. Highly significant Visual-N-back correlation with UPDRS-III may implicate the shared motor-visuospatial neural pathways. Visual-N-back/PGI delayed recall domains are promising in characterizing PD-MCI stage.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Delayed recall (memory); Fronto-striatal and posterior cortical syndrome; Mild cognitive impairment; Montreal Cognitive Assessment Test (MoCA); Parkinson’s disease; Visuo-spatial function

Year:  2020        PMID: 32192853     DOI: 10.1016/j.jocn.2020.03.015

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  5 in total

1.  Frontal lobe metabolic alterations characterizing Parkinson's disease cognitive impairment.

Authors:  Shefali Chaudhary; S Senthil Kumaran; Vinay Goyal; M Kalaivani; Gauri Shanker Kaloiya; Rajesh Sagar; Nalin Mehta; Achal Kumar Srivastava; N R Jagannathan
Journal:  Neurol Sci       Date:  2020-07-29       Impact factor: 3.307

2.  Morphological analysis of subcortical structures for assessment of cognitive dysfunction in Parkinson's disease using multi-atlas based segmentation.

Authors:  S Sivaranjini; C M Sujatha
Journal:  Cogn Neurodyn       Date:  2021-03-14       Impact factor: 3.473

3.  Analysis of neuropathological comorbid conditions in elderly patients with mild cognitive impairment in a tertiary care center in South India.

Authors:  Alex Baby Paul; Dakshin Sitaram Padmanabhan; Vineeth Suresh; Sunav Nellai Nayagam; Niveditha Kartha; George Paul; Priya Vijayakumar
Journal:  J Family Med Prim Care       Date:  2022-03-18

4.  Exploring the feasibility of technological visuo-cognitive training in Parkinson's: Study protocol for a pilot randomised controlled trial.

Authors:  Julia Das; Rosie Morris; Gill Barry; Rodrigo Vitorio; Paul Oman; Claire McDonald; Richard Walker; Samuel Stuart
Journal:  PLoS One       Date:  2022-10-07       Impact factor: 3.752

Review 5.  The influence of white matter hyperintensity on cognitive impairment in Parkinson's disease.

Authors:  Hailing Liu; Bin Deng; Fen Xie; Xiaohua Yang; Zhenchao Xie; Yonghua Chen; Zhi Yang; Xiyan Huang; Shuzhen Zhu; Qing Wang
Journal:  Ann Clin Transl Neurol       Date:  2021-07-26       Impact factor: 4.511

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.